PERRIGO COMPANY PLC (PRGO) — Analysis Summary
PERRIGO COMPANY PLC (PRGO) has a market cap of $1.40B with year-over-year revenue growth of -2.8%. Net margin stands at -33.5%. The stock trades at a P/E ratio of -0.8.
Key Takeaways
- Revenue changed -2.8% year-over-year
- Net margin of -33.5%
- P/E ratio of -0.8
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, PRGO posted revenue growth of -2.8% and trades at a P/E of -0.8.
PERRIGO COMPANY PLC (PRGO)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Operating margin at -36.9% — material operating losses
Net margin at -43.5% — significant losses
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
8,100
Headquarters
DUBLIN 2, L2
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$1.16
Dividend Yield
11.47%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.